Search
Phosphoaminophosphonic acid guanylate ester
go.drugbank.com/drugs/DB02082ExperimentalA non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+. … The nucleotide is a potent stimulator of adenylate cyclase.
(1R,2S)-2-Phenylcyclopropanaminium
go.drugbank.com/drugs/DB02665ExperimentalThis monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders.
Ad5-nCoV
go.drugbank.com/drugs/DB15655Investigational)[L12675] with an expected completion in December 2020. … [L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906
Alrizomadlin
go.drugbank.com/drugs/DB17549InvestigationalAlrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. It is being investigated in cancers.[A257281,A257286]
Tilmicosin
go.drugbank.com/drugs/DB11471InvestigationalVet approvedTilmicosin is a macrolide antibiotic. It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease associated with _Mannheimia haemolytica_.
AZD2389
go.drugbank.com/drugs/DB22104InvestigationalAZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g. … NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).
Distigmine
go.drugbank.com/drugs/DB13694InvestigationalDistigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. … It improves detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity [A27176].
Sovleplenib
go.drugbank.com/drugs/DB17557InvestigationalIt is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia). … Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk).
Refanezumab
go.drugbank.com/drugs/DB14908InvestigationalRefanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).